Palvella Therapeutics, Inc.(PVLA US)
$162.28+9.356.11%
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions USD (ex. Per Share) | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | ||||
| -Cost of Revenue | - | - | - | - | ||||
| Gross Profit | - | - | - | - | ||||
| -Operating Expenses | 11.9 | 14.1 | 38.6 | 45.6 | ||||
| +Selling, General & Admin | 3.1 | 5.9 | 15.8 | 17.5 | ||||
| +General And Administrative Expenses | 3.1 | 5.9 | 15.8 | 17.5 | ||||
| +Research and Development | 8.8 | 8.2 | 22.8 | 28.1 | ||||
| +Other Operating Expenses | - | - | - | - | ||||
| Operating Income | -11.9 | -14.1 | -38.6 | -45.6 | ||||
| +Non Operating Income | 36.8 | -7.7 | -6.3 | -7.4 | ||||
| +Interest Income, Net | 6.3 | -4.3 | -3.2 | -3.7 | ||||
| +Interest Income | 6.3 | - | 2.6 | 2.9 | ||||
| -Interest Expense | - | 4.3 | 5.8 | 6.6 | ||||
| +Other Non-Op Income | 30.6 | -3.3 | -3.1 | -3.7 | ||||
| Pretax Income | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Income Tax Expense | - | - | - | - | ||||
| Income from Cont Ops | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Net Extraordinary Losses | - | - | - | - | ||||
| +Discounted operations | - | - | - | - | ||||
| +XO & Accounting Changes | - | - | - | - | ||||
| Income Incl. MI | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Minority Interests | - | - | - | - | ||||
| Net Income, GAAP | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Prfrrd Div & Other | - | - | - | - | ||||
| Net Income Avail To Common | 17.9 | -17.4 | -41.7 | -49.3 | ||||
| Weighted Average Shs Out | 1,268,000 | 2,226,000 | 11,251,250 | 46,453,544 | ||||
| EPS | 14.7 | -7.8 | -3.7 | -4.2 | ||||
| Weighted Average Shs Out Dil | 1,268,000 | 2,226,000 | 11,251,250 | 46,453,544 | ||||
| EPS Diluted | 14.7 | -7.8 | -3.7 | -4.2 | ||||
| Millions USD (ex. Per Share) | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | ||||
| -Cost of Revenue | - | - | - | - | ||||
| Gross Profit | - | - | - | - | ||||
| -Operating Expenses | 11.9 | 14.1 | 38.6 | 45.6 | ||||
| +Selling, General & Admin | 3.1 | 5.9 | 15.8 | 17.5 | ||||
| +General And Administrative Expenses | 3.1 | 5.9 | 15.8 | 17.5 | ||||
| +Research and Development | 8.8 | 8.2 | 22.8 | 28.1 | ||||
| +Other Operating Expenses | - | - | - | - | ||||
| Operating Income | -11.9 | -14.1 | -38.6 | -45.6 | ||||
| +Non Operating Income | 36.8 | -7.7 | -6.3 | -7.4 | ||||
| +Interest Income, Net | 6.3 | -4.3 | -3.2 | -3.7 | ||||
| +Interest Income | 6.3 | - | 2.6 | 2.9 | ||||
| -Interest Expense | - | 4.3 | 5.8 | 6.6 | ||||
| +Other Non-Op Income | 30.6 | -3.3 | -3.1 | -3.7 | ||||
| Pretax Income | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Income Tax Expense | - | - | - | - | ||||
| Income from Cont Ops | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Net Extraordinary Losses | - | - | - | - | ||||
| +Discounted operations | - | - | - | - | ||||
| +XO & Accounting Changes | - | - | - | - | ||||
| Income Incl. MI | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Minority Interests | - | - | - | - | ||||
| Net Income, GAAP | 18.7 | -17.4 | -41.7 | -49.3 | ||||
| -Prfrrd Div & Other | - | - | - | - | ||||
| Net Income Avail To Common | 17.9 | -17.4 | -41.7 | -49.3 | ||||
| Weighted Average Shs Out | 1,268,000 | 2,226,000 | 11,251,250 | 46,453,544 | ||||
| EPS | 14.7 | -7.8 | -3.7 | -4.2 | ||||
| Weighted Average Shs Out Dil | 1,268,000 | 2,226,000 | 11,251,250 | 46,453,544 | ||||
| EPS Diluted | 14.7 | -7.8 | -3.7 | -4.2 | ||||